Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab

Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab Publisher

Alaeen H¹ ; Toosi R¹ ; Mahmoudi H¹ ; Balighi K¹ ; Tavakolpour S¹ ; Teimoupour A² ; Daneshpazhooh M¹

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Women's Dermatology Published:2019

Abstract

Background: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a first-line treatment for PV. Objective: The primary and secondary aims were to evaluate anti-Dsg and EDTA-treated anti-Dsg ELISA and clinical response before and 3 months after RTX in treatment-naive and previously treated patients, respectively. In addition, we compared the short-term efficacy of RTX between these groups. Methods: Seventy-five patients with PV who received RTX (500 mg weekly for 4 weeks or 1000 mg 2 weeks apart) and prednisolone were followed for 3 months. Thirty-seven treatment-naive newly diagnosed (group A) and 38 relapsed patients (group B) were included. Disease activity was scored with the Pemphigus Disease Area Index (PDAI). Clinical response was also assessed. Serum samples were collected at two points and examined for anti-Dsg1/3 and EDTA-treated anti-Dsg1/3. Conformational anti-Dsg values were calculated by subtracting EDTA-treated from conventional anti-Dsg values. Results: The correlation of conventional and conformational anti-Dsg values was perfect (correlation coefficient > 0.98; p < .001) at every time point for both anti-Dsgs. There was no difference with regard to PDAI and anti-Dsg values between the two groups at baseline. The frequency of responders was significantly higher in group A (100%) than in group B (89%; p = .006). Three patients relapsed, and five patients had persistent disease activity in group B. After 3 months, conventional and conformational anti-Dsg values were significantly higher in group B compared with group A (anti-Dsg3: p = .017 and .021, respectively; anti-Dsg1: p = .014 and .016, respectively). Total and scalp PDAI were significantly lower in group A than in group B (p = .042 and .016, respectively). Conclusion: EDTA-treated anti-Dsg ELISA had no added value. Using RTX as first-line treatment in patients with PV appears to be associated with better clinical response and immunologic profile than delayed treatment in the short term. © 2019

Related Docs

View other Related Docs

1. Current Status and Prospects for the Diagnosis of Pemphigus Vulgaris, Expert Review of Clinical Immunology (2021)

2. Immunologic Prediction of Relapse in Patients With Pemphigus Vulgaris (Pv) in Clinical Remission, Journal of the American Academy of Dermatology (2016)

3. Estimated Cut-Off Values for Pemphigus Severity Classification According to Pemphigus Disease Area Index (Pdai), Autoimmune Bullous Skin Disorder Intensity Score (Absis), and Anti-Desmoglein 1 Autoantibodies, BMC Dermatology (2020)

4. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

5. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)

6. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)

7. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)

8. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (39)

Kamran Balighi (32)

Style	Citing Format
MLA	Alaeen H, et al.. "Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab." International Journal of Women's Dermatology, vol. 5, no. 5, 2019, pp. 372-377.
APA	Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, Daneshpazhooh M (2019). Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab. International Journal of Women's Dermatology, 5(5), 372-377.
Chicago	Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, Daneshpazhooh M. "Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab." International Journal of Women's Dermatology 5, no. 5 (2019): 372-377.
Harvard	Alaeen H et al. (2019) 'Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab', International Journal of Women's Dermatology, 5(5), pp. 372-377.
Vancouver	Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, et al.. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab. International Journal of Women's Dermatology. 2019;5(5):372-377.
BibTex	@article{ author = {Alaeen H and Toosi R and Mahmoudi H and Balighi K and Tavakolpour S and Teimoupour A and Daneshpazhooh M}, title = {Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab}, journal = {International Journal of Women's Dermatology}, volume = {5}, number = {5}, pages = {372-377}, year = {2019} }
RIS	TY - JOUR AU - Alaeen H AU - Toosi R AU - Mahmoudi H AU - Balighi K AU - Tavakolpour S AU - Teimoupour A AU - Daneshpazhooh M TI - Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab JO - International Journal of Women's Dermatology VL - 5 IS - 5 SP - 372 EP - 377 PY - 2019 ER -

Style

Citing Format

MLA

Alaeen H, et al.. "Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab." International Journal of Women's Dermatology, vol. 5, no. 5, 2019, pp. 372-377.

APA

Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, Daneshpazhooh M (2019). Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab. International Journal of Women's Dermatology, 5(5), 372-377.

Chicago

Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, Daneshpazhooh M. "Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab." International Journal of Women's Dermatology 5, no. 5 (2019): 372-377.

Harvard

Alaeen H et al. (2019) 'Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab', International Journal of Women's Dermatology, 5(5), pp. 372-377.

Vancouver

Alaeen H, Toosi R, Mahmoudi H, Balighi K, Tavakolpour S, Teimoupour A, et al.. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab. International Journal of Women's Dermatology. 2019;5(5):372-377.

BibTex

@article{ author = {Alaeen H and Toosi R and Mahmoudi H and Balighi K and Tavakolpour S and Teimoupour A and Daneshpazhooh M}, title = {Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab}, journal = {International Journal of Women's Dermatology}, volume = {5}, number = {5}, pages = {372-377}, year = {2019} }

RIS

TY - JOUR
AU - Alaeen H
AU - Toosi R
AU - Mahmoudi H
AU - Balighi K
AU - Tavakolpour S
AU - Teimoupour A
AU - Daneshpazhooh M
TI - Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab
JO - International Journal of Women's Dermatology
VL - 5
IS - 5
SP - 372
EP - 377
PY - 2019
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract